Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Every 2 Week Doxil and Gemcitabine in Recurrent Ovarian Cancer

NCT00312650 is registered in ClinicalTrials.gov with Women and Infants Hospital of Rhode Island as lead sponsor.

NCT NCT00312650
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00312650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Every 2 Week Doxil and Gemcitabine in Recurrent Ovarian Cancer
Lead sponsor
Women and Infants Hospital of Rhode Island
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2006
Completion date
May 31, 2006
Enrollment
24
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian carcinoma